Johnson & Johnson (JNJ) operating KPIs
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson iNVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — Worldwide operational (constant-currency) growth YoY (%) (%)
Form 8-K EX-99.2 Segment Sales Schedule
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | INVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — Worldwide operational (constant-currency) growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2022 | Jan 1, 2023 | -17.2% | +13.4 pts | Form 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗ |
| FY2021 | Jan 2, 2022 | -30.6% | -39.2 pts | Form 8-K (a2021q4exhibit991.htm, filed 2022-01-25) ↗ |
| FY2020 | Jan 3, 2021 | 8.6% | +24.2 pts | Form 8-K (a2020q4exhibit991.htm, filed 2021-01-26) ↗ |
| FY2019 | Dec 29, 2019 | -15.6% | +5.2 pts | Form 8-K (a2019q4exhibit991.htm, filed 2020-01-22) ↗ |
| FY2018 | Dec 30, 2018 | -20.8% | +0.3 pts | Form 8-K (a2018q4exhibit9915.htm, filed 2019-01-22) ↗ |
| FY2017 | Dec 31, 2017 | -21.1% | – | Form 8-K (a8k2017q4exhibit9915.htm, filed 2018-01-23) ↗ |
Breakdown
What makes up invokana / invokamet (canagliflozin) [reported separately through fy2022q4] — worldwide operational (constant-currency) growth yoy (%)
Cite this data
StockData. (2026). Johnson & Johnson INVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — Worldwide operational (constant-currency) growth YoY (%) (%), annual FY2017–FY2022 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_invokana_ops_yoy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.